PDCD1 and glioblastoma: However, one retrospective study indicated that a single PD-1 blocking agent with better tolerance (i.e., Pembrolizumab) was unable to improve the OS of patients who suffered from recurrent high-grade glioblastoma (HCG), which represented an OS of 4 months [47] (Table 1).